Johnson & Johnson reported positive Phase 3 survival outcomes for Tecvayli (teclistamab) in an earlier‑line multiple myeloma setting, supporting the drugmaker’s strategy to expand use beyond later lines. The MajesTEC‑9 data showed survival benefit metrics that J&J will use to pursue label expansion and reposition the bispecific as a treatment for earlier disease stages. The readout could shift competitive dynamics in multiple myeloma by accelerating adoption of T‑cell engaging bispecifics in earlier lines and raising the bar for other developers seeking to move cell‑ and bispecific therapies earlier in the treatment sequence.